|
BRD3 bromodomain 1 (24-144 aa) (GST-tagged), Human recombinant
A protein involved in chromatin targeting
Product Overview
Product Name: BRD3 bromodomain 1 (24-144 aa) (GST-tagged), Human recombinant
Alternate Name/Synonyms: ORFX; RING3L; Bromodomain containing protein 3; RING3-like protein
Gene Symbol: BRD3
Accession #: Q15059
Gene ID: 8019
Source: E. coli
Appearance: Liquid
Physical Form Description: 50 mM Tris, pH 7.5, containing 500 mM sodium chloride, 5% glycerol, and 5 mM β-mercaptoethanol.
Molecular Weight: 41.2 kDa (24-144 aa + NT GST Tag)
Purity by SDS-PAGE: ≥95%
Purity by HPLC: N/A
Endotoxin Level: N/A
Biological Activity: N/A
Reconstitution Instructions: N/A
Storage Temp.: -80°C
Shipping: Dry ice
Background Information: The acetylation of histone lysine residues plays a crucial role in the epigenetic regulation of gene transcription. A bromodomain is a protein domain that recognizes acetylated lysine residues such as those on the N-terminal tails of histones. This recognition is often a prerequisite for protein-histone association and chromatin remodeling. These domains function in the linking of protein complexes to acetylated nucleosomes, thereby controlling chromatin structure and gene expression. Thus, bromodomains serve as “readers” of histone acetylation marks regulating the transcription of target promoters. The BET family of proteins, defined by tandem Bromodomains and an Extra Terminal domain, include BRD2, BRD3, BRD4, and BRDT. The BET proteins play a key role in many cellular processes, including inflammatory gene expression, mitosis, and viral/host interactions. The isolated individual or tandem bromodomains of BRD3 have been shown to bind acetylated histone tails, serving to couple histone acetylation marks to the transcriptional regulation of target promoters. Small molecule inhibitors of these interactions hold promise as useful therapeutics for human disease.
Amino Acid Sequence: N/A
Handling: Centrifuge the vial prior to opening
USAGE: For Research Use Only! Not For Use in Humans. |